What is Systemic sclerosis?
Systemic sclerosis, also known as scleroderma, is a rare autoimmune connective tissue disorder characterized by widespread inflammation, blood vessel abnormalities, and excessive collagen production leading to skin thickening and internal organ damage. The condition affects approximately 1 in 10,000 people worldwide, with women being affected three to four times more often than men. Systemic sclerosis typically develops between ages 30-50, though it can occur at any age. While there is no cure, early diagnosis and treatment can significantly improve outcomes and quality of life for patients living with this complex condition.
Key statistics
| Statistic | Value |
|---|---|
| Prevalence | ~1 in 10,000 (10-20 cases per 100,000) |
| Female to male ratio | 3-4:1 |
| Typical age of onset | 30-50 years |
| 10-year survival rate | 80-85% (varies by subtype) |
Symptoms
Primary symptoms: Skin thickening and tightening, Raynaud’s phenomenon, joint pain and stiffness, fatigue, gastrointestinal problems, breathing difficulties, kidney complications.
Early symptoms often include Raynaud’s phenomenon, where fingers and toes turn white, blue, then red in response to cold or stress. Skin changes typically begin with swelling and gradually progress to thickening and tightening, particularly affecting the hands, face, and arms.
Common manifestations include gastroesophageal reflux, difficulty swallowing, joint pain and morning stiffness, dry eyes and mouth, and small red spots on the skin called telangiectasias. Many patients experience significant fatigue and may develop digital ulcers on fingertips.
Serious complications can affect major organs. Pulmonary fibrosis causes progressive scarring of lung tissue, while pulmonary arterial hypertension increases pressure in lung blood vessels. Scleroderma renal crisis involves sudden severe high blood pressure and kidney failure. Gastrointestinal dysmotility can lead to severe malabsorption and nutritional deficiencies. Heart involvement may cause arrhythmias, heart failure, or pericarditis.
Causes and risk factors
Systemic sclerosis is an autoimmune disease where the immune system mistakenly attacks healthy connective tissue, leading to inflammation, blood vessel damage, and excessive collagen production. The exact trigger remains unknown, but research suggests a combination of genetic predisposition and environmental factors.
Genetic factors play a role, with certain HLA genes and other genetic variants increasing susceptibility. However, systemic sclerosis is not directly inherited and rarely affects multiple family members.
Environmental triggers may include exposure to silica dust, organic solvents, certain medications, and viral infections. Some studies suggest links to Epstein-Barr virus and cytomegalovirus. Smoking appears to increase risk and worsen outcomes.
Risk factors include female sex, age 30-50, family history of autoimmune diseases, and occupational exposures. Certain ethnic groups, particularly those of European and African descent, show higher prevalence rates.
Prevention
Currently, there is no known way to prevent systemic sclerosis as it is an autoimmune condition with unclear triggers. Since the disease is not inherited in a simple genetic pattern, genetic testing for prevention is not routinely recommended.
However, individuals can reduce their risk of developing complications by avoiding known environmental triggers such as silica dust exposure, minimizing contact with organic solvents, and not smoking. For those with family members affected by autoimmune diseases, maintaining awareness of early symptoms like Raynaud’s phenomenon may enable earlier medical evaluation and intervention.
Regular health screenings and maintaining overall immune system health through proper nutrition, exercise, and stress management may be beneficial, though these measures do not guarantee prevention.
Complications
Without proper treatment, systemic sclerosis can lead to severe, life-threatening complications affecting multiple organ systems. Pulmonary complications are the leading cause of death, including progressive pulmonary fibrosis that reduces lung function and pulmonary arterial hypertension that strains the heart.
Scleroderma renal crisis can develop suddenly, causing kidney failure and requiring immediate treatment. Gastrointestinal complications may lead to severe malnutrition, bacterial overgrowth, and in rare cases, perforation of the bowel.
Cardiac involvement can result in heart failure, dangerous arrhythmias, and sudden cardiac death. Severe digital ischemia may progress to gangrene requiring amputation. Joint contractures and skin tightening can cause significant disability and functional impairment.
Psychological complications including depression and anxiety are common due to the chronic nature of the disease, physical changes, and uncertain prognosis. Early intervention and comprehensive care can prevent or minimize many of these complications.
Diagnosis
Diagnosing systemic sclerosis requires careful evaluation by a rheumatologist, as symptoms can develop gradually and mimic other conditions. The 2013 ACR/EULAR classification criteria include skin thickening and various combinations of digital ulcers, telangiectasias, abnormal nail fold capillaries, Raynaud’s phenomenon, specific autoantibodies, and pulmonary arterial hypertension or interstitial lung disease.
Blood tests examine specific autoantibodies including antinuclear antibodies (ANA), anti-centromere antibodies, anti-topoisomerase I (Scl-70), and anti-RNA polymerase III antibodies. These help determine disease subtype and prognosis.
Imaging studies include high-resolution computed tomography (HRCT) of the chest to detect lung involvement, echocardiogram to assess heart function and pulmonary pressures, and barium swallow to evaluate gastrointestinal motility.
Specialized tests may include pulmonary function tests, six-minute walk test, nail fold capillaroscopy to examine small blood vessels, and esophageal manometry to assess swallowing function. Skin biopsy is rarely needed but may help in uncertain cases.
Treatment
Treatment for systemic sclerosis focuses on managing symptoms and preventing organ damage, as there is no cure. A multidisciplinary approach involving rheumatologists, pulmonologists, cardiologists, and other specialists provides optimal care.
Immunosuppressive medications include mycophenolate for skin and lung involvement, and tocilizumab, an IL-6 receptor antagonist that may help with skin thickening. Nintedanib, an antifibrotic agent, is approved for treating systemic sclerosis-associated interstitial lung disease.
Symptom-specific treatments include calcium channel blockers for Raynaud’s phenomenon, proton pump inhibitors for gastroesophageal reflux, and ACE inhibitors for blood pressure control and renal crisis prevention. Endothelin receptor antagonists or phosphodiesterase-5 inhibitors may be used for pulmonary arterial hypertension.
Supportive therapies include physical and occupational therapy to maintain joint mobility and function, wound care for digital ulcers, and nutritional support for gastrointestinal complications. Cyclophosphamide may be considered for rapidly progressive lung disease.
Prognosis
The prognosis for systemic sclerosis varies significantly depending on the subtype and organs involved. Limited cutaneous systemic sclerosis generally has a better prognosis than diffuse cutaneous disease, with 10-year survival rates of approximately 90% versus 70-80% respectively.
Factors associated with worse outcomes include diffuse skin involvement, older age at onset, male sex, cardiac involvement, pulmonary arterial hypertension, and certain antibody profiles, particularly anti-RNA polymerase III antibodies which increase renal crisis risk.
Early diagnosis and treatment significantly improve outcomes. Many patients can maintain good quality of life with proper management, though the disease course is unpredictable. Some individuals experience rapid progression within the first few years, while others have slowly progressive or stable disease for many years.
Modern treatments have substantially improved survival rates, particularly for renal crisis and pulmonary arterial hypertension. Ongoing research continues to identify new therapeutic targets and improve long-term outcomes.
Quality of life
Living with systemic sclerosis requires significant lifestyle adaptations, but many patients maintain fulfilling lives with proper support and management strategies. Protecting against cold exposure is crucial for managing Raynaud’s phenomenon – wearing gloves, using hand warmers, and avoiding air conditioning can help.
Exercise remains important despite joint stiffness and fatigue. Low-impact activities like swimming, walking, and stretching exercises help maintain flexibility and cardiovascular health. Physical therapy can provide personalized exercise programs and joint protection techniques.
Dietary modifications may include eating smaller, frequent meals for gastroparesis, avoiding acidic foods for reflux, and ensuring adequate nutrition despite absorption issues. Working with a dietitian can be valuable for managing gastrointestinal symptoms.
Mental health support is essential, as depression and anxiety are common. Counseling, support groups, and stress management techniques help patients cope with the chronic nature of the disease and physical changes. Connecting with other patients through organizations like the Scleroderma Foundation provides valuable peer support.
Work accommodations may include ergonomic modifications, flexible schedules, and avoiding extreme temperatures. Many patients continue working with appropriate adjustments.
Pregnancy and fertility
Systemic sclerosis can affect fertility and pregnancy outcomes, requiring careful planning and monitoring. Women with stable, limited disease generally have successful pregnancies, while those with active or severe disease face higher risks.
Pregnancy complications may include preeclampsia, intrauterine growth restriction, and preterm delivery. Renal involvement and pulmonary arterial hypertension significantly increase maternal and fetal risks. Some medications like mycophenolate must be discontinued before conception due to teratogenic effects.
Pre-pregnancy counseling should involve rheumatology, maternal-fetal medicine, and other relevant specialists to optimize disease management and medication safety. Disease activity should ideally be stable for at least six months before conception.
Fertility may be impaired in some patients, particularly those who have received cyclophosphamide treatment. Fertility preservation options should be discussed before starting potentially gonadotoxic therapies.
Close monitoring throughout pregnancy and postpartum is essential, as some women experience disease flares during or after pregnancy.
Children
Juvenile systemic sclerosis is extremely rare, affecting fewer than 1 in 100,000 children. When it occurs, it often presents differently than adult disease, with more prominent inflammatory features and different patterns of organ involvement.
Children may experience more joint contractures and growth problems due to skin tightening. The disease course in children can be more variable, with some experiencing rapid progression while others have milder symptoms.
Treatment approaches are similar to adults but require careful attention to growth, development, and medication dosing. Pediatric rheumatology expertise is essential for optimal management. Educational support and psychological counseling help children and families cope with this challenging diagnosis.
When to see a doctor
Seek immediate medical attention for symptoms of scleroderma renal crisis including sudden severe headache, very high blood pressure (>150/85), vision changes, seizures, or decreased urination. Severe breathing difficulties, chest pain, or signs of heart failure also require emergency care.
Schedule prompt medical evaluation for new or worsening Raynaud’s phenomenon, especially with digital ulcers or color changes, progressive skin thickening or tightening, difficulty swallowing, persistent dry cough, or unexplained fatigue and joint pain.
Regular monitoring is essential for all patients with systemic sclerosis, including periodic assessment of lung function, heart function, kidney function, and blood pressure. Annual screening helps detect organ involvement before symptoms develop.
Early recognition and treatment of complications significantly improve outcomes, making regular medical follow-up crucial for all patients with systemic sclerosis.
Regional context
Limited data exists on systemic sclerosis prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. European studies suggest prevalence rates similar to global averages, but genetic and environmental factors specific to these regions may influence disease patterns.
We invite healthcare professionals and researchers from these regions to contribute their clinical experience and epidemiological data to the Global Medical Journal to better understand regional variations in systemic sclerosis presentation and outcomes.
Environmental factors such as occupational exposures in mining, agriculture, and industrial activities common in these regions may influence disease risk and should be considered in clinical evaluation and prevention strategies.
Research and clinical trials
Current research focuses on understanding the molecular mechanisms driving fibrosis, developing biomarkers for early detection and monitoring, and testing novel therapeutic approaches. Promising areas include antifibrotic agents, immunomodulatory therapies, and regenerative medicine approaches.
Recent breakthroughs include the approval of nintedanib for systemic sclerosis-associated interstitial lung disease and ongoing studies of tocilizumab for skin manifestations. Researchers are investigating JAK inhibitors, complement inhibitors, and novel antifibrotic compounds.
Cell therapy approaches using mesenchymal stem cells and other regenerative strategies show promise in early studies. Precision medicine approaches aim to match specific treatments to individual patient profiles based on autoantibody patterns and genetic markers.
Patients interested in clinical trials can search for opportunities at ClinicalTrials.gov. Participation in research studies helps advance understanding and treatment of this rare disease while potentially providing access to innovative therapies.
Frequently asked questions
Is systemic sclerosis hereditary?
Systemic sclerosis is not directly inherited, but genetic factors influence susceptibility. The risk of developing the condition is only slightly higher in family members, and specific genetic testing is not routinely recommended for relatives.
Will my skin changes get worse over time?
Skin involvement varies significantly between patients. Some experience progression in the first few years followed by stabilization or even improvement, while others have slowly progressive changes. Early treatment can help minimize skin thickening and prevent complications.
Can I still work with systemic sclerosis?
Many people with systemic sclerosis continue working with appropriate accommodations. This may include ergonomic modifications, flexible schedules, temperature control, and avoiding certain exposures. Occupational therapy can help identify necessary workplace adjustments.
How often should I be monitored for complications?
Regular monitoring typically includes yearly lung function tests, echocardiograms, blood pressure checks, and laboratory studies. More frequent monitoring may be needed depending on your specific symptoms and organ involvement. Your healthcare team will determine the appropriate schedule.
Are there any dietary restrictions I should follow?
While there’s no specific systemic sclerosis diet, managing gastrointestinal symptoms may require modifications such as smaller frequent meals, avoiding acidic foods, and ensuring adequate nutrition. A dietitian can provide personalized recommendations based on your symptoms.
Support and resources
Scleroderma Foundation – Comprehensive patient support, education, and research funding
Website: scleroderma.org
EURORDIS (European Rare Disease Organisation) – European advocacy and support
Website: eurordis.org
National Organization for Rare Disorders (NORD) – Patient assistance and advocacy
Website: rarediseases.org
Orphanet – Comprehensive rare disease information portal
Website: orpha.net
World Health Organization (WHO) – Global health information and resources
Website: who.int
International Scleroderma Network – Global patient organization coalition
Various national organizations provide local support and resources
Related conditions
GMJ News Desk. “Systemic sclerosis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/systemic-sclerosis/ Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included. Was this article helpful?Cite this page
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.